What is IDE892 studying for MTAP-deleted advanced solid tumors?

IDE892 is being studied to assess its safety, effectiveness, and how it is processed by the body in adults with advanced solid tumors that have a specific MTAP gene deletion. The study also evaluates IDE892 combined with IDE397 to target tumor vulnerabilities. IDEAYA Biosciences is leading this research to address treatment needs for patients whose cancers have progressed after standard therapies.

Who may be eligible for this MTAP-deleted advanced solid tumors clinical trial?

Adults 18 years or older with advanced solid tumors that have MTAP deletion may be eligible. Participants should have progressed after standard treatments and be able to provide tissue and blood samples. Both males and females can participate, and participants must have good organ function and an ECOG performance status of 0 or 1. Please review eligibility criteria for more details.

Is there any cost to participate in this MTAP-deleted advanced solid tumors clinical trial?

Study-related care, including the study drugs and all trial visits, is provided at no cost. Personal travel and related expenses may vary and are not guaranteed to be covered. Participants should plan accordingly for any additional costs.

Actively Recruiting

Phase 1

Age: 18Years +

All Genders

ID07277413

Evaluating IDE892 Alone and with IDE397 for Adults with MTAP-Deleted Advanced Solid Tumors

Led by IDEAYA Biosciences · Updated on 2026-08-05

260

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating the safety, effectiveness, and how the body processes IDE892 when used alone or combined with other drugs like IDE397 in adults with advanced solid tumors that have a specific genetic change called MTAP deletion. This study focuses on participants whose cancer has progressed after standard treatment and aims to address a significant medical need by targeting vulnerabilities in tumors with this genetic deletion. Participants will receive IDE892 alone or combined with IDE397, an oral drug that blocks MAT2A, to improve treatment impact while maintaining safety. The study includes dose escalation phases to find the right dose and expansion phases to further assess the treatments effects. Different groups include those with various solid tumors and those with non-small cell lung cancer NSCLC, with treatment cycles lasting 21 days. During the study, participants will have blood and tumor tissue samples collected for biomarker testing and monitoring. Researchers will assess side effects, how well the drug is tolerated, tumor response, and drug levels in the body over approximately two years. Visits include regular safety checks and scans to evaluate tumors. Participants must comply with scheduled visits, treatment plans, and tests throughout the study.

CONDITIONS

Brief Title

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Are 18 years of age or older at the time of signing informed consent.
Have a confirmed diagnosis of locally advanced, recurrent, or metastatic solid tumor with MTAP deletion.
Willing and able to provide blood and tumor tissue samples for biomarker testing.
Evidence of homozygous loss of MTAP or MTAP deletion.
Have at least one measurable lesion per RECIST version 1.1.
Have ECOG Performance Status of 0 or 1.
Have a life expectancy greater than 3 months.
Have adequate bone marrow and organ function.
Able to swallow and retain orally administered study drug.
Willing and able to follow the study visits, treatment plan, and procedures.
Male and female participants must be willing to use contraception.
For NSCLC participants: advanced or metastatic disease progressed after prior platinum chemotherapy and PD-1/PD-L1 inhibitor, with no more than 3 prior treatment lines.
For urothelial cancer, mesothelioma, pancreatic, or biliary tract cancers: must have progressed after at least one prior treatment line and no more than 3 prior treatment lines.

You will not qualify if you...

Known symptomatic brain metastases requiring high-dose corticosteroids.
Known primary central nervous system malignancy.
Other malignancies within 2 years prior to first dose (with some exceptions).
Impaired cardiac function or significant cardiac diseases.
Uncontrolled pleural, peritoneal, or pericardial effusion requiring drainage.
History of severe infections within 4 weeks before treatment.
Hypertension above 150/100 mmHg not controlled by medication.
Other acute or chronic medical or psychiatric conditions.
History of immunodeficiency or positive HIV test.
Known or suspected viral hepatitis.
Unrecovered adverse reactions to previous antitumor treatment worse than grade 1.
Recent chemotherapy, immunotherapy, biologic treatments, or investigational drugs within defined timeframes.
Current radiation toxicity or recent radiation therapy.
Use of strong CYP inhibitors or inducers and other specified drugs before first dose.
Use of proton pump inhibitors within 7 days prior to first dose.
Use of drugs with risk for QT prolongation within 2 weeks prior to first dose.
Previous treatment with MAT2A or PRMT inhibitors.
Major surgery within 4 weeks before study entry.
Prior irradiation to more than 25% of bone marrow.
Known or suspected hypersensitivity to IDE892.

Research Team

IDEAYA Clinical Trials

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Evaluating IDE892 Alone and with IDE397 for Adults with MTAP-Deleted Advanced Solid Tumors

On this page

AI-Summary

What this Trial Is About

Brief Title

Who Can Participate

Eligibility Criteria

Research Team

Not the Right Trial for You?

On this page

Who Can Participate

Eligibility Criteria